Astellas-Medivation Prostate-Cancer Drug Phase III Trial Ended Early
This article was originally published in PharmAsia News
Executive Summary
A prostate-cancer drug developed by Astellas Pharma and Medivation has succeeded so well in a Phase III trial it was halted early so participants on a placebo could receive the treatment.